<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G</submissionType>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001725721</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
	      <securitiesClassTitle>Common Stock, $0.001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001853921</issuerCik>        <issuerName>Scribe Therapeutics Inc.</issuerName>

    <issuerCusips>
					<issuerCusipNumber>811033109</issuerCusipNumber>
				</issuerCusips>

        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>1150 Marina Village Parkway</com:street1>
                    <com:city>Alameda</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94501</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	           <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
						      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>AH Bio Fund II, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>2385075.00</soleVotingPower>
                          <sharedVotingPower>0.00</sharedVotingPower>
                          <soleDispositivePower>2385075.00</soleDispositivePower>
                         <sharedDispositivePower>0.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2385075.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>12.6</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>AH Equity Partners Bio II, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>2385075.00</soleVotingPower>
                          <sharedVotingPower>0.00</sharedVotingPower>
                          <soleDispositivePower>2385075.00</soleDispositivePower>
                         <sharedDispositivePower>0.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2385075.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>12.6</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>AH Bio Fund III, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>697650.00</soleVotingPower>
                          <sharedVotingPower>0.00</sharedVotingPower>
                          <soleDispositivePower>697650.00</soleDispositivePower>
                         <sharedDispositivePower>0.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>697650.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>3.7</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>AH Equity Partners Bio III, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>697650.00</soleVotingPower>
                          <sharedVotingPower>0.00</sharedVotingPower>
                          <soleDispositivePower>697650.00</soleDispositivePower>
                         <sharedDispositivePower>0.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>697650.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>3.7</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Marc L. Andreessen</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>3082725.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>3082725.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3082725.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>16.3</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Benjamin A. Horowitz</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>3082725.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>3082725.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3082725.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>16.3</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>Scribe Therapeutics Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>1150 Marina Village Parkway, Alameda, CA, 94501.</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>The names of the persons filing this report (collectively, the "Reporting Persons") are:

AH Bio Fund II, L.P.						("AH Bio II")
AH Equity Partners Bio II, L.L.C.			("AH EP Bio II")
AH Bio Fund III, L.P.					("AH Bio III")
AH Equity Partners Bio III, L.L.C.			("AH EP Bio III")
Marc L. Andreessen					("Andreessen")
Benjamin A. Horowitz					("Horowitz")

The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>The address for each of the Reporting Persons is:

Andreessen Horowitz
2865 Sand Hill Road, Suite 101
Menlo Park, CA 94025</principalBusinessOfficeOrResidenceAddress>        <citizenship>AH Bio II, AH EP Bio II, AH Bio III and AH EP Bio III were all organized in Delaware. Andreessen and Horowitz are both United States citizens. </citizenship>      </item2>

        <item3>
		        <notApplicableFlag>Y</notApplicableFlag>

      </item3>



    <item4>
    <amountBeneficiallyOwned>Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.

The Reporting Persons' beneficial ownership of the Issuer's securities consists of (i) 2,385,075 shares of common stock directly held by AH Bio II for itself and as nominee for AH Bio Fund II-B, L.P. ("AH Bio II-B") and (ii) 697,650 shares of common stock directly held by AH Bio III for itself and as nominee for AH Bio Fund III-B, L.P. ("AH Bio III-B"), AH Bio Fund III-Q, L.P. ("AH Bio III-Q") and CLF Partners II, LP ("CLF II").

AH EP Bio II is the general partner of AH Bio II and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer held of record by AH Bio II for itself and as nominee for AH Bio II-B. Andreessen and Horowitz are managing members of AH EP Bio II and may be deemed to have shared voting and shared dispositive power over the shares held of record by AH Bio II for itself and as nominee.

AH EP Bio III is the general partner of AH Bio III and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer held of record by AH Bio III for itself and as nominee for AH Bio III-B, AH Bio III-Q and CLF II. Andreessen and Horowitz are managing members of AH EP Bio III and may be deemed to have shared voting and shared dispositive power over the shares held of record by AH Bio III for itself and as nominee.</amountBeneficiallyOwned>    <classPercent>Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 18,931,680 shares of common stock outstanding as of August 31, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on September 2, 2026.</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>
	          <notApplicableFlag>Y</notApplicableFlag>


    </item5>


        <item6>
	              <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>Under certain circumstances set forth in the limited partnership agreements of each of  AH Bio II, AH Bio II-B, AH Bio III, AH Bio III-B, AH Bio III-Q, and CLF II and the limited liability company agreements of AH EP Bio II and AH EP Bio III, the general partner and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by each such entity of which they are a partner or a member, as the case may be.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
		     </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                    <notApplicableFlag>Y</notApplicableFlag>

      </item10>
    </items>

		<exhibitInfo>Exhibit 24.1	Power of Attorney for Marc L. Andreessen, dated June 23, 2023.

Exhibit 24.2	Power of Attorney for Benjamin A. Horowitz, dated June 22, 2023.

Exhibit 99.1	Joint Filing Agreement</exhibitInfo>

	    <signatureInformation>
      <reportingPersonName>AH Bio Fund II, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Phil Hathaway</signature>
        <title>By AH Equity Partners Bio II, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 1)</title>
        <date>11/16/2026</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>AH Equity Partners Bio II, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Phil Hathaway</signature>
        <title>By Phil Hathaway, Chief Operating Officer</title>
        <date>11/16/2026</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>AH Bio Fund III, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Phil Hathaway</signature>
        <title>By AH Equity Partners Bio III, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 2)</title>
        <date>11/16/2026</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>AH Equity Partners Bio III, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Phil Hathaway</signature>
        <title>By Phil Hathaway, Chief Operating Officer</title>
        <date>11/16/2026</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Marc L. Andreessen</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Phil Hathaway</signature>
        <title>By Phil Hathaway, Attorney-in-Fact</title>
        <date>11/16/2026</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Benjamin A. Horowitz</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Phil Hathaway</signature>
        <title>By Phil Hathaway, Attorney-in-Fact</title>
        <date>11/16/2026</date>
      </signatureDetails>

    </signatureInformation>


	 <signatureComments>Note 1:  AH Bio Fund II, L.P. for itself and as nominee for AH Bio Fund II-B, L.P.

Note 2:  AH Bio Fund III, L.P. for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP.</signatureComments>
  </formData>


    </edgarSubmission>
